Erasca, Inc. Lease, Cost
Erasca, Inc. (ERAS) reported Lease, Cost of $2.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-11
- Erasca, Inc. lease, cost for the quarter ending 2026-06-30 was $2.15M, a 1.22% increase year-over-year.
- Erasca, Inc. lease, cost for the quarter ending 2026-03-31 was $1.84M, a 18.62% decline year-over-year.
- Erasca, Inc. lease, cost for the quarter ending 2025-12-31 was $2.13M, a 3.55% increase year-over-year.
- Erasca, Inc. lease, cost for the quarter ending 2025-09-30 was $2.06M, a 14.63% decline year-over-year.
- Erasca, Inc. lease, cost for fiscal 2025 was $8.58M, a 17.78% decline from fiscal 2024.
- Erasca, Inc. lease, cost for fiscal 2024 was $10.44M, a 8.25% decline from fiscal 2023.
- Erasca, Inc. lease, cost for fiscal 2023 was $11.38M, a 47.73% increase from fiscal 2022.
- Erasca, Inc. lease, cost for fiscal 2022 was $7.70M, a 175.00% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.15M 10-Q · filed 2026-08-11 | $3.99M 10-Q · filed 2026-08-11 | $6.12M derived: sum of 3 quarters · filed 2026-08-11 | $8.18M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $1.84M 10-Q · filed 2026-05-11 | $3.97M derived: sum of 2 quarters · filed 2026-05-11 | $6.03M derived: sum of 3 quarters · filed 2026-05-11 | $8.16M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.19M derived: sum of 2 quarters · filed 2026-03-12 | $6.32M derived: sum of 3 quarters · filed 2026-08-11 | $8.58M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $2.06M 10-Q · filed 2025-11-12 | $4.19M derived: sum of 2 quarters · filed 2026-08-11 | $6.45M 10-Q · filed 2025-11-12 | $8.51M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $2.13M 10-Q · filed 2026-08-11 | $4.39M 10-Q · filed 2026-08-11 | $6.44M derived: sum of 3 quarters · filed 2026-08-11 | $8.86M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $2.26M 10-Q · filed 2026-05-11 | $4.32M derived: sum of 2 quarters · filed 2026-05-11 | $6.73M derived: sum of 3 quarters · filed 2026-05-11 | $9.95M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.47M derived: sum of 2 quarters · filed 2026-03-12 | $7.69M derived: sum of 3 quarters · filed 2026-03-12 | $10.44M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $2.42M 10-Q · filed 2025-11-12 | $2.40M 10-Q · filed 2024-11-12 | $5.64M derived: sum of 2 quarters · filed 2025-11-12 | $8.38M 10-Q · filed 2025-11-12 | $8.40M 10-Q · filed 2024-11-12 | $11.16M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $3.22M 10-Q · filed 2025-08-12 | $3.20M 10-Q · filed 2024-08-12 | $5.96M 10-Q · filed 2025-08-12 | $5.90M 10-Q · filed 2024-08-12 | $8.74M derived: sum of 3 quarters · filed 2025-08-12 | $11.54M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $2.74M 10-Q · filed 2025-05-13 | $2.70M 10-Q · filed 2024-05-08 | $5.52M derived: sum of 2 quarters · filed 2025-05-13 | $8.32M derived: sum of 3 quarters · filed 2025-05-13 | $11.12M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $5.58M derived: sum of 2 quarters · filed 2025-03-20 | $8.38M derived: sum of 3 quarters · filed 2025-03-20 | $11.38M 10-K · filed 2025-03-20 | $11.40M 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $2.80M 10-Q · filed 2024-11-12 | $5.60M derived: sum of 2 quarters · filed 2024-11-12 | $8.60M 10-Q · filed 2024-11-12 | $11.30M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $2.80M 10-Q · filed 2024-08-12 | $5.80M 10-Q · filed 2024-08-12 | $8.50M derived: sum of 3 quarters · filed 2024-08-12 | $11.10M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $3.10M 10-Q · filed 2024-05-08 | $5.70M derived: sum of 2 quarters · filed 2024-05-08 | $8.30M derived: sum of 3 quarters · filed 2024-05-08 | $9.60M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $5.20M derived: sum of 2 quarters · filed 2024-03-27 | $6.50M derived: sum of 3 quarters · filed 2024-03-27 | $7.70M 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $2.60M 10-Q · filed 2023-11-09 | $3.90M derived: sum of 2 quarters · filed 2023-11-09 | $5.10M 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-10 | $2.50M 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | $1.20M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $2.80M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |